OpenEvidence operates a specialized medical superintelligence platform that serves as a "brain extender" for clinicians by synthesizing answers exclusively from trusted medical journals and data. Its orchestration of proprietary, sub-specialist AI models – coordinated by a central “conductor” agent – is designed to surface the highest-quality, most accurate medical guidance available. The service is free to doctors and ad-supported, and it is already used daily by more than 40 % of U.S. physicians across over 10,000 hospitals and medical centers. In December 2025 alone, the system powered roughly 18 million clinical consultations, up from about 3 million per month a year prior, and over the past year doctors using OpenEvidence treated more than 100 million Americans. The rapid adoption helped the company surpass $100 million in annual revenue less than a year after building its commercial team. OpenEvidence differentiates itself through exclusive content partnerships with the New England Journal of Medicine, the American Medical Association, the National Comprehensive Cancer Network, and the American College of Cardiology, among others. These relationships, combined with its narrow training corpus and multi-agent architecture, have positioned the company as the most widely used AI tool by U.S. physicians.

Total raised

$735M

Funding rounds

4

Latest round

Series D

Latest activity

Jan 2026